Vomiting  >>  fosaprepitant  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
fosaprepitant / Generic mfg.
NCT00990821: A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)

Completed
1
188
US
90 mg MK-0517 (PS80), 100 mg MK-0517 (PS80), 100 MK-0517 (PS80) + 2 mg midazolam, 115 mg MK-0517 (PS80), 150 mg MK-0517 (PS80), 40 mg MK-0517 (non-PS80), 100 mg MK-0517 (non-PS80), 150 mg MK-0517 (Non-PS80), Placebo, 40 mg Aprepitant, 125 mg Aprepitant, 2 mg Midazolam
Merck Sharp & Dohme LLC
Chemotherapy-Induced Nausea and Vomiting, Postoperative Nausea and Vomiting
12/05
01/06
NCT00945321: A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)

Completed
1
42
US
aprepitant 165 mg, Comparator: aprepitant 185 mg, Comparator: fosaprepitant 150 mg, Comparator: aprepitant with food
Merck Sharp & Dohme LLC
Chemotherapy-Induced Nausea and Vomiting
03/09
03/09
NCT01111851: Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)

Completed
1
16
Europe
Fosaprepitant 150 mg, MK0517, Aprepitant 165 mg, MK0869, Aprepitant 250 mg, Dexamethasone (12-8-16-16 mg), Dexamethasone, Dexamethasone (12-8-8-16 mg), Ondansetron, MK0999
Merck Sharp & Dohme LLC
Chemotherapy-Induced Nausea and Vomiting (CINV)
10/10
10/10
NCT00818259: A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)

Terminated
1
92
NA
Experimental: aprepitant, Emend, MK-0869, Experimental: fosaprepitant, Emend injection, Fosaprepitant Dimeglumine, MK-0517, Comparator: ondansetron, Zofran, Ondansetron, Dexamethasone
Merck Sharp & Dohme LLC
Chemotherapy-Induced Nausea and Vomiting
01/14
01/14

Download Options